Selection Against Undifferentiated Human Embryonic Stem Cells by a Cytotoxic Antibody Recognizing Podocalyxin-Like Protein-1
Version of Record online: 20 MAR 2008
Copyright © 2008 AlphaMed Press
Volume 26, Issue 6, pages 1454–1463, June 2008
How to Cite
Choo, A. B., Tan, H. L., Ang, S. N., Fong, W. J., Chin, A., Lo, J., Zheng, L., Hentze, H., Philp, R. J., Oh, S. K.W. and Yap, M. (2008), Selection Against Undifferentiated Human Embryonic Stem Cells by a Cytotoxic Antibody Recognizing Podocalyxin-Like Protein-1. STEM CELLS, 26: 1454–1463. doi: 10.1634/stemcells.2007-0576
- Issue online: 2 JAN 2009
- Version of Record online: 20 MAR 2008
- Manuscript Accepted: 8 MAR 2008
- Manuscript Received: 19 JUL 2007
- Human embryonic stem cells;
- Monoclonal antibodies;
- Podocalyxin-like protein-1
Future therapeutic applications of differentiated human embryonic stem cells (hESC) carry a risk of teratoma formation by contaminating undifferentiated hESC. We generated 10 monoclonal antibodies (mAbs) against surface antigens of undifferentiated hESC, showing strong reactivity against undifferentiated, but not differentiated hESC. The mAbs did not cross react with mouse fibroblasts and showed weak to no reactivity against human embryonal carcinoma cells. Notably, one antibody (mAb 84) is cytotoxic to undifferentiated hESC and NCCIT cells in a concentration-dependent, complement-independent manner. mAb 84 induced cell death of undifferentiated, but not differentiated hESC within 30 minutes of incubation, and immunoprecipitation of the mAb-antigen complex revealed that the antigen is podocalyxin-like protein-1. Importantly, we observed absence of tumor formation when hESC and NCCIT cells were treated with mAb 84 prior to transplantation into severe combined immunodeficiency mice. Our data indicate that mAb 84 may be useful in eliminating residual hESC from differentiated cells populations for clinical applications.
Disclosure of potential conflicts of interest is found at the end of this article.